PATENT CLAIM ANALYSIS

Application Number: 15749963
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "235500"]

Abstract:
A compound of Formula I is provided: or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and/or prevention of cancer, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington's disease, chronic viral infections such as HCV and HIV, depression, and obesity. The invention also relates to a process for manufacturing compounds of Formula I.

Claim (Index 2):
The compound according to  claim 1 , wherein Q is H.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 88.0
- Lexical Diversity: 1.88679
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14619589', '15072534', '14076016', '14765556', '15546251']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8044181094078219
- 35 USC 102 Novelty (BERT): 0.58060639232138
- Combined Prediction Score: 0.7820369376991777
- Mean Citation Score: 378.49669200000005
- Max Citation Score: 465.86142
- Similarity Product: 454.6616747536612

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test